

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**COMPLETION OF FILING NATIONAL PHASE OF PCT APPLICATION**  
**UNDER RULE 35 USC 371 AND 37 CFR 1.494(C) OR 1.495(C)****BOX PCT****COMPLETION  
For PCT Cases Only**In re PATENT APPLICATION of

Inventor(s): James P. Burnie et al.

Appln. No.: 09 | 889,314  
Series Code ↑      Serial No. ↑Atty. Dkt. P 0281578  
M# \_\_\_\_\_ Client Ref \_\_\_\_\_

National Phase Field

Based on PCT | GB00 | 00237  
↑ Country Code & Year

Title: MEDICAMENT

Date: November 20, 2001

**FILING OF ITEM(S) LATE IN PCT/USA NATIONAL CASE**Asst. Commissioner of Patents  
Washington, DC 20231

Sir:

The following completes the filing of the subject application under Rule 494(c)/495(c). Please accept the following attached items:

1. Missing Requirements Notice (PCT/DO/EO/905)  copy attached  not yet received
2.  **Signed Declaration**  Original  Facsimile/Copy  with spec/claims attached
3.  **Translation** of the International Application into English including:
  - a.  Request;
  - b.  Abstract
  - c.  Spec. and Claims;  Translation verification
  - e.  sheets Drawing which are:  informal  formal of size  A4  11"
4.  Copy of **International Search Report** (ISR) attached (   page(s))
  - a.  plus Annex of family members (   page(s))
5. **Information Disclosure Statement** including
  - a.  From PTO-1449 listing documents
  - b.  Copies of document(s) listed on Form PTO-1449
  - c.  A concise explanation of ISR references is given in the ISR
6.  **Assignment** and cover sheet. Please return the recorded assignment to the undersigned.
7.  Copy of Power to international application agent.
8. 2 (No.) Small Entity Statement(s) establishing "small entity" status under Rules 9 & 27.
9.  Formal Drawings:    sheet(s)  informal;  formal of size:  A4  11"
10.  Please immediately start national examination procedures (35 USC 371(f))

11.  Attached: Sequence Listing with computer readable copy
12.  Preliminary Amendment:
13.  Basic U.S. National fee per Rule 492(a)(1)-(4) was previously timely filed.:
14. **Calculation of remaining fees due (if any):** based on amended claim(s) per above item

12 (above) or item(s) in PAT-112 (filed previously)       12       14       17       25

15. **CLAIMS FEES**     previously paid     paid herewith as follows:

- 15A. Small Entity Statement     Herewith     Previously Filed

			Large/Small Entity		Fee Code
16. Total Effective Claims		minus 20 =	x \$18/\$9	+	966/967
17. Independent Claims		minus 3 =	x \$84/\$42	+	964/965
18. If any proper multiple dependent claim (ignore improper) is present,			\$280/\$140	+	968/969
19. Filing Declaration late, fee paid	<input type="checkbox"/> previously	<input checked="" type="checkbox"/> now	\$130/\$65	+65	154/254
20.			<b>SUBTOTAL</b>	<b>\$65</b>	
21. <b>Original due date:</b>	October 23, 2001				
22. Petition is hereby made to extend the <u>original</u> due date to	(1 mo)	\$110/\$55 =	+55	115/215	
cover the date this response is filed for which the requisite fee	(2mos)	\$400/\$200 =		116/216	
is attached	(3mos)	\$920/\$460 =		117/217	
	(4mos)	\$1,440/\$720 =		118/218	
23. If "non-English" box 3 is X'd, add Rule 17(k) processing fee .....		\$130	+0	156	
24. If "assignment" box 6 is X'd, add recording fee .....		\$40	+40	581	
25.		<b>TOTAL FEE ENCLOSED =</b>	<b>\$160</b>		

(Our Deposit Account No. 03-3975)  
 (Our Order No. 050885      0281578  
 C#                          M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

**Pillsbury Winthrop LLP  
Intellectual Property Group**

1600 Tysons Boulevard  
McLean, VA 22102  
Tel: (703) 905-2000

By Atty: Bonnie Weiss McLeod      Reg. No. 43,255  
 Sig: Bonnie Weiss McLeod      Fax: (703) 905-2500  
 Tel: (703) 905-2219

BWM/kmh

**NOTE: File in duplicate with PTO receipt (PAT-103A) and attachments**

11/21/2001 LLANDGRA 00000020 09889314

01 FC:254                          65.00 DP  
02 FC:215                          55.00 DP

Rec'd PCT/PTO 20 NOV 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

James P. Burnie et al.

Application No. 09/889,314

Filed: July 16, 2001

Title: MEDICAMENT

**BOX SEQUENCE**

Group Art Unit: Unassigned

Examiner: Unassigned

\* \* \* \* \*

**RESPONSE WITH SEQUENCE LISTING**


Hon. Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 23, 2001, attached please find a copy of the "Sequence Listing" in computer readable format along with a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §1.821-1.825.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By:   
Bonnie Weiss McLeod  
Registration No. 43,255

1600 Tysons Boulevard  
McLean, VA 22102  
(703) 905-2000  
(703) 905-2500 Facsimile

Date: November 20, 2001

Enclosure: Statement to Support Filing  
Sequence Listing (including electronic copy)



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.		FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/889314		BURNIE J	P0281578
PILLSBURY WINTHROP LLP 1600 TYSONS BOULEVARD MCLEAN, VA 22102		INTERNATIONAL APPLICATION NO.	
		PCT/GB00/00237	
		I.A. FILING DATE	PRIORITY DATE
		28 JAN 00	05 FEB 99
		23 AUG 2001	
DATE MAILED:			

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- Other: \_\_\_\_\_

**APPLICANT MUST PROVIDE:**

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE  
CALL:

- (703) 308-4216, for Rules interpretation,
- (703) 308-4212, for CRF submission help,
- (703) 287-0200, for PatentIn software help.

Barbara A. Campbell

Telephone: 703-305-3631